Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 10/20 | 0.32 |
| ▸ | HTR2A | P28223 | 10/20 | 0.32 |
| ▸ | DRD2 | P14416 | 7/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803066 | 0.79 | HTR1A (0.40) | ADAM17HTR1AHTR2ADRD2CNR1 | |
| SCHEMBL803049 | 0.76 | ADAM17 (0.45) | ADAM17HTR1AHTR2ADRD2 | |
| SCHEMBL25597828 | 0.71 | ALOX15 (0.38) | — | |
| SCHEMBL25597830 | 0.70 | DRD2 (0.36) | HTR1AHTR2ADRD2 | |
| SCHEMBL12049049 | 0.66 | MTNR1A (0.43) | HTR1AHTR2ADRD2MTNR1A | |
| SCHEMBL22021891 | 0.63 | — | — | |
| SCHEMBL11947839 | 0.63 | HTR1A (0.46) | ADAM17HTR1AHTR2ADRD2 | |
| SCHEMBL11947805 | 0.63 | ADAM17 (0.54) | ADAM17HTR1AHTR2ADRD2 | |
| SCHEMBL21117711 | 0.62 | HTR2A (0.35) | HTR2AMTNR1A | |
| SCHEMBL12230597 | 0.62 | CRBN (0.38) | ADAM17MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | ADAM17 241/4885HTR1A 842/4885HTR2A 1936/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | ADAM17 145/4885HTR1A 593/4885HTR2A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.